Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chaiqinzhijie decoction is a Traditional Chinese Medicine (TCM) herbal formulation developed by The Second Hospital of Tianjin Medical University. It is specifically indicated for the treatment of cough variant asthma (CVA), particularly the 'liver-fire invading lung' syndrome type. As a decoction, it is a multi-component mixture of herbal extracts designed to clear liver fire, regulate lung qi, and resolve phlegm to alleviate chronic cough symptoms. In clinical research, it has been evaluated in randomized controlled trials to compare its efficacy and safety against standard inhaled therapies such as budesonide and formoterol fumarate (Symbicort Turbuhaler).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chaiqinzhijie decoction.